These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24740238)

  • 1. A marginal benefit approach for vaccinating influenza "superspreaders".
    Skene KJ; Paltiel AD; Shim E; Galvani AP
    Med Decis Making; 2014 May; 34(4):536-49. PubMed ID: 24740238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policy resistance undermines superspreader vaccination strategies for influenza.
    Wells CR; Klein EY; Bauch CT
    PLoS Comput Biol; 2013; 9(3):e1002945. PubMed ID: 23505357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the optimal target age group for seasonal influenza vaccination in Japan.
    Tsuzuki S; Baguelin M; Pebody R; van Leeuwen E
    Vaccine; 2020 Jan; 38(4):752-762. PubMed ID: 31735503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluations of childhood influenza vaccination: a critical review.
    Newall AT; Jit M; Beutels P
    Pharmacoeconomics; 2012 Aug; 30(8):647-60. PubMed ID: 22788257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
    de Boer PT; Backer JA; van Hoek AJ; Wallinga J
    BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluation.
    Hill EM; Petrou S; Forster H; de Lusignan S; Yonova I; Keeling MJ
    PLoS Comput Biol; 2020 Oct; 16(10):e1008278. PubMed ID: 33021983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
    de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
    Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study.
    Yue M; Dickens BL; Yoong JS; I-Cheng Chen M; Teerawattananon Y; Cook AR
    Value Health; 2019 Dec; 22(12):1345-1354. PubMed ID: 31806190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.
    Basta NE; Chao DL; Halloran ME; Matrajt L; Longini IM
    Am J Epidemiol; 2009 Sep; 170(6):679-86. PubMed ID: 19679750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers.
    Werker GR; Sharif B; Sun H; Cooper C; Bansback N; Anis AH
    Vaccine; 2014 Feb; 32(6):677-84. PubMed ID: 24355089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.
    Jit M; Newall AT; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):834-40. PubMed ID: 23357859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted vaccination in healthy school children - Can primary school vaccination alone control influenza?
    Thorrington D; Jit M; Eames K
    Vaccine; 2015 Oct; 33(41):5415-5424. PubMed ID: 26314627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64 years old.
    Raj SM; Chughtai AA; Sharma A; Tan TC; MacIntyre CR
    Vaccine; 2019 Sep; 37(40):5979-5985. PubMed ID: 31473001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.
    Giglio N; Gentile A; Lees L; Micone P; Armoni J; Reygrobellet C; Crépey P
    Hum Vaccin Immunother; 2012 Mar; 8(3):312-22. PubMed ID: 22330959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.